
Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.
What Happened: Wood’s enthusiasm centers on what she describes as a transformative convergence of technologies that could revolutionize medical treatment and drug discovery.